Renvela brings up questions about how to choose a phosphate binder for patients with chronic kidney disease

The new product, Renvela, brings up questions about how to choose a phosphate binder for patients with chronic kidney disease.

These have similar efficacy for lowering phosphate levels...but vary in adverse effects, cost, and pill burden.

Aluminum hydroxide isn't used chronically anymore. Aluminum accumulates and leads to bone disease, dementia, and death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote